Nussdorf Glenn H's Form 4 filing
Organogenesis Holdings Inc. (ORGO) · filed Nov 3, 2025
- Accession no.
- 0002064832-25-000013
- Filed
- Nov 3, 2025
- Trade date
- May 14-Jun 10, 2025
- Filing delay
- 173 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $1.10M. Open-market sales total $80.8K. It was filed 173 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nussdorf Glenn HCIK 0001244191 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | Class A Common Stock | PPurchaseAcquired | +251,001 | $3.09F1 | +$775,593.09 | 251,001 | Indirect | |
| May 15, 2025 | Class A Common Stock | PPurchaseAcquired | +107,494 | $2.99F2 | +$321,407.06 | 358,495 | Indirect | |
| Jun 9, 2025 | Class A Common Stock | SSaleDisposed | −4,156 | $3.50F3 | −$14,546 | 354,339 | Indirect | |
| Jun 10, 2025 | Class A Common Stock | SSaleDisposed | −18,620 | $3.56F4 | −$66,287.2 | 335,719 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Referenced by the price of 1 transaction in Table I.